Eli Lilly has gained attention in recent time thanks to its weight-loss drugs. Demand for these products is driving revenue higher.
In the most recent trading session, Eli Lilly (LLY) closed at $865.97, indicating a +0.99% shift from the previous trading day.
Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.
Eli Lilly is having great success in the market for weight loss treatments. Viking is working on a candidate that could potentially outperform Eli Lilly's.
Eli Lilly and Co. (LLY) announced on its WeChat account Friday that it has won approval from Chinese regulators to sell tirzepatide for weight loss in the country.
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in the key Asian market.
Since the start of 2020, Eli Lilly's ( NYSE: LLY ) stock price chart has been straight up and to the right, up 553% and currently trading at $848.74.
Eli Lilly & Co.'s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers.
Eli Lilly's surging valuation has made the case for a stock split. Many growth stocks have deployed stock splits in recent years, including Eli Lilly rival Novo Nordisk.
Eli Lilly (LLY) concluded the recent trading session at $941.60, signifying a -0.93% move from its prior day's close.
While the last two major global pandemics were more than 100 years apart, a few international agencies warn of the increased potential for more frequent pandemics. This is admittedly a concerning and uncomfortable thought, considering the severe societal damage that occurred as a result of the Covid-19 pandemic.